Nanomedicine and the complement paradigm.

Area of Science:

• Immunology
• Nanomedicine
• Pharmacology

Background:

• Idiosyncratic reactions to nanopharmaceuticals are increasingly linked to complement activation.
• Newly developed complement inhibitors offer potential strategies to mitigate these adverse events.

Purpose of the Study:

• To discuss the role of complement in nanopharmaceutical infusion reactions.
• To explore the use of complement inhibitors for preventing adverse responses.
• To advocate for genetic association studies to understand the genetic basis of these reactions.

Main Methods:

• Literature review and discussion on complement's role in nanomedicine.
• Analysis of the potential application of complement inhibitors.
• Call for genetic association studies.

Main Results:

• Complement activation is a significant factor in idiosyncratic nanopharmaceutical reactions.
• Complement inhibitors show promise in preventing infusion-related adverse effects.
• Genetic factors, particularly within the immune system, likely underlie individual susceptibility.

Conclusions:

• Understanding complement pathways is crucial for safe nanopharmaceutical development.
• Targeting complement activation with inhibitors is a viable strategy for mitigating adverse reactions.
• Genetic association studies are essential to identify individuals at risk for nanomedicine-related adverse responses.